Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Collaboration Agreement to provide Metabolomic Profiling Services

Published: Wednesday, March 05, 2014
Last Updated: Wednesday, March 05, 2014
Bookmark and Share
Metabolon Inc will assist Human Longevity Inc to build the world’s largest and most complete human genotype, microbiome and phenotype database.

Metabolon, Inc. announces the signing of an agreement with newly-launched Human Longevity Inc., whereby Metabolon will provide biochemical profiling services to assist HLI in its mission to tackle diseases of aging by building the world’s largest and most complete human genotype, microbiome and phenotype database. In the initial term of the agreement Metabolon will carry out small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules to end points of disease and gene mutations.
“We are delighted to be aligned with HLI and the world-renowned scientific minds behind this new company. It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery.”
HLI cofounders are J. Craig Venter, Ph.D., Robert Hariri, M.D., Ph.D. and Peter H. Diamandis, M.D. Dr. Venter, who is well known for leading Celera to the successful sequencing of the human genome, has been a member of Metabolon’s Scientific Advisory Board since 2003.
Under the agreement Metabolon will apply its leading metabolomics technology to augment the genetic and microbiome information HLI is collecting. Metabolon’s metabolomic approach identifies the full complement of metabolites present in a human biological specimen. Metabolomics is important because quantifying and understanding the full picture of circulating biochemicals in the body can help researchers get a clearer picture of that individual’s health status, and provide markers and pathways associated with disease and drug action. In addition, Metabolon will collaborate with HLI to identify small molecule biomarkers of disease, which Metabolon may then use to develop small molecule diagnostic tests.
Commenting on the agreement Dr. Venter said, “The establishment of HLI is the next step beyond the sequencing of the human genome, and may at last provide useful clinical information for the treatment of disease that was lacking from genome mapping alone. Metabolon is a visionary and leader in the field of metabolomics, and I have great confidence in the company’s technology and ability to add significant value to HLI. Because of my position as a member of Metabolon’s Scientific Advisory Board, I have a deep personal appreciation of the company’s impressive methods and scientific expertise.”
John Ryals, Ph.D., Metabolon’s chief executive officer, said, “We are delighted to be aligned with HLI and the world-renowned scientific minds behind this new company. It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Closes $15M Financing Round
Metabolon has announced that it has closed a financing that raised $15 million from new investor Essex Woodlands, a leading healthcare growth equity firm.
Friday, August 12, 2016
Study Shows Quantose IR™ Measures Insulin Sensitivity Better
Results were recently published online by the Journal of Clinical Endocrinology & Metabolism.
Wednesday, April 01, 2015
Metabolon, Baylor Partner to Screen for Inborn Errors of Metabolism
The two-year, exclusive agreement will provide global Metabolomic-Assisted Pathway Screening (MAPS) services for individuals with suspected inborn errors of metabolism (IEMs).
Thursday, September 04, 2014
Metabolon, Geisinger Partner on Prediabetes Study
Metabolon will sponsor a pilot study to evaluate its Quantose IRTM test as a monitor of glycemic control in people with prediabetes.
Friday, June 27, 2014
New Study Reveals Interplay between Genetics and Metabolism in Complex Disease
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments.
Saturday, May 17, 2014
Interplay between Genetics and Metabolism in Complex Disease Revealed
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments
Friday, May 16, 2014
Metabolon Enters into Collaboration with GSK
Agreement will see Metabolon provide metabolomic profiling services to GlaxoSmithKline.
Wednesday, May 14, 2014
Metabolon Debuts New Client Portal at Bio-IT World Expo
MetaboLync™ is a cloud-based solution for sharing, visualizing, and analyzing metabolomics data.
Wednesday, April 30, 2014
Microbes and Metabolites Fuel an Ambitious Aging Project
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Wednesday, March 12, 2014
Metabolon Closes $15 Million Series E Financing
Company raises $15 million through the issuance of preferred stock.
Monday, January 06, 2014
Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Metabolon and Bostwick Laboratories Announce Marketing Agreement
Under the Agreement Bostwick will market Prostarix™, a non-invasive urine test for stratifying prostate cancer risk.
Monday, November 04, 2013
Metabolon Announces Findings from Two Major Diabetes Outcomes Studies
This provides further evidence that the Quantose test identifies individuals at risk for type 2 diabetes earlier and more accurately than traditional risk factors alone.
Tuesday, June 25, 2013
Impaired Metabolism in Cystic Fibrosis Lung Epithelial Cells Revealed by Metabolic Analysis
Metabolon announces publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”.
Monday, October 25, 2010
Metabolon Awarded US Patent for Metabolic Biomarkers of Efficacy of PPAR Affecting Drugs
The USPTO awarded the patent to Metabolon on October 5, 2010.
Thursday, October 21, 2010
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos